Imbio, LLC: Spesana Partners with Imbio to Add Quantitative Imaging to Its Molecular Diagnostics Decision Support Platform

MEMPHIS, Tenn., Feb. 24, 2021 /PRNewswire/ -- Spesana, a healthcare platform focused for molecular diagnostics-driven decision support and clinical collaboration, and Imbio, a leading provider of artificial intelligence (AI) solutions for medical imaging analysis, have joined forces to bring quantitative imaging results to the frontlines of patient care. "Spesana's technology uniquely provides molecular diagnostic selection and ordering, tracks test status and displays results with a unified view of data from EHRs, prior authorizations, approved drugs and pathways," said Carla Balch, CEO of Spesana. "Imaging biomarkers have the potential to significantly improve patient diagnosis, treatment, and understanding of response to therapy. This partnership, which combines Imbio's expertise in imaging biomarkers with Spesana's real world data and Instant Collaborations with molecular and imaging experts, has the potential to further deliver on the promise of more personalized healthcare." "Imaging AI can and does generate additional, and sometimes intimidating, but valuable information," said Mike Hostetler, Director of Marketing and Sales of Imbio. "The challenge for caregivers and health systems is ingesting and acting on ...Full story available on Benzinga.com